CSL Ltd., of King of Prussia, Pa., launched AEGIS-I, a phase IIb study of CSL112, a formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture.